ACADIA Pharmaceuticals Stock Forecast, Price & News

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACAD shares have increased by 41.1% and is now trading at $52.01.
View which stocks have been most impacted by COVID-19.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 1 hold rating, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACADIA Pharmaceuticals stock.
View analyst ratings for ACADIA Pharmaceuticals or view MarketBeat's top 5 stock picks.

Wall Street analysts have given ACADIA Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ACADIA Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

1,448 employees have rated ACADIA Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among ACADIA Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings data on Monday, November, 9th. The biopharmaceutical company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.16. The biopharmaceutical company had revenue of $120.58 million for the quarter, compared to the consensus estimate of $118.82 million. ACADIA Pharmaceuticals had a negative return on equity of 40.35% and a negative net margin of 63.92%. The business's quarterly revenue was up 27.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.29) earnings per share.
View ACADIA Pharmaceuticals' earnings history.

ACADIA Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Wednesday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $430-450 million, compared to the consensus revenue estimate of $443.75 million.

16 analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $42.00 to $72.00. On average, they expect ACADIA Pharmaceuticals' stock price to reach $61.25 in the next year. This suggests a possible upside of 17.8% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Some companies that are related to ACADIA Pharmaceuticals include BeiGene (BGNE), Astellas Pharma (ALPMY), Genmab A/S (GMAB), Takeda Pharmaceutical (TKPYY), Genmab A/S (GNMSF), Shiseido (SSDOY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), UCB (UCBJF), Royalty Pharma (RPRX), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), CureVac (CVAC), Horizon Therapeutics Public (HZNP), BioMarin Pharmaceutical (BMRN) and Elanco Animal Health (ELAN).
View all of ACAD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (0.60%), Peregrine Capital Management LLC (0.11%), Wealthstreet Investment Advisors LLC (0.09%), DNB Asset Management AS (0.03%), First Midwest Bank Trust Division (0.01%) and Kestra Advisory Services LLC (0.01%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals.

ACAD stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, First Midwest Bank Trust Division, Peregrine Capital Management LLC, Profit Investment Management LLC, Exchange Traded Concepts LLC, and Wealthstreet Investment Advisors LLC. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, James M Daly, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals or view top insider-selling stocks.

ACAD stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Hohimer Wealth Management LLC, Hohimer Wealth Management LLC, Kestra Advisory Services LLC, Sowell Financial Services LLC, and Pacer Advisors Inc..
View insider buying and selling activity for ACADIA Pharmaceuticals or or view top insider-buying stocks.

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACAD stock can currently be purchased for approximately $52.01.

ACADIA Pharmaceuticals has a market capitalization of $8.27 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. ACADIA Pharmaceuticals employs 580 workers across the globe.

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]